Have a personal or library account? Click to login
The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction Cover

The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction

Global Heart
Volume 16 (2021): Issue 1
By: Ahmed Farouk Alaarag,  Ahmed Mohamed Hamam and  Osama Ahmed Amin  
Open Access
|Jan 2021

References

  1. 1 Babiker A, Hassan M, Muhammed S, et al. Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review. Clin Cardiol. 2020; 43(3): 222–234. DOI: 10.1002/clc.23299
    Back to article
  2. 2 Elgharably A, Gomaa AI, Crossey MM, Norsworthy PJ, Waked I, Taylor-Robinson SD. Hepatitis C in Egypt – past, present, and future. Int J Gen Med. 2016; 10: 1–6. Published 2016 Dec 20. DOI: 10.2147/IJGM.S119301
    Back to article
  3. 3 Abdel-Razek W, Hassany M, El-Sayed MH, et al. Hepatitis C Virus in Egypt: Interim report from the world’s largest national program. Clin Liver Dis (Hoboken). 2020; 14(6): 203–206. Published 2020 Jan 29. DOI: 10.1002/cld.868
    Back to article
  4. 4 Vassalle C, Petta S, Pepe A, Craxi A, Bondin M, Cacoub P. Expert opinion on managing chronic HCV in patients with cardiovascular disease. Antivir Ther. 2018; 23(Suppl 2): 35–46. DOI: 10.3851/IMP3248
    Back to article
  5. 5 Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses. 2013; 5(5): 1292–1324. Published 2013 May 23. DOI: 10.3390/v5051292
    Back to article
  6. 6 Milner KL, van der Poorten D, Trenell M, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology. 2010; 138(3): 932–941.e3. DOI: 10.1053/j.gastro.2009.11.050
    Back to article
  7. 7 Dalbeni A, Romano S, Bevilacqua M, et al. Beneficial effects of DAAs on cardiac function and structure in hepatitis C patients with low-moderate liver fibrosis. J Viral Hepat. 2020; 27(11): 1214–1221. DOI: 10.1111/jvh.13355
    Back to article
  8. 8 Poller W, Haghikia A, Kasner M, et al. Cardiovascular involvement in chronic hepatitis C virus infections – insight from novel antiviral therapies. J Clin Transl Hepatol. 2018; 6(2): 161–167. DOI: 10.14218/JCTH.2017.00057
    Back to article
  9. 9 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC [published correction appears in Eur Heart J. 2016 Dec 30]. Eur Heart J. 2016; 37(27): 2129–2200. DOI: 10.1093/eurheartj/ehw128
    Back to article
  10. 10 Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60(8): 646–649. DOI: 10.1002/bjs.1800600817
    Back to article
  11. 11 Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62(16): e147–e239. DOI: 10.1016/j.jacc.2013.05.019
    Back to article
  12. 12 Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging [published correction appears in Eur Heart J Cardiovasc Imaging. 2016Apr;17(4):412] [published correction appears in Eur Heart J Cardiovasc Imaging. 2016Sep;17(9):969]. Eur Heart J Cardiovasc Imaging. 2015; 16(3): 233–270. DOI: 10.1093/ehjci/jev014
    Back to article
  13. 13 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419. DOI: 10.1007/BF00280883
    Back to article
  14. 14 Domont F, Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int. 2016; 36(5): 621–627. DOI: 10.1111/liv.13064
    Back to article
  15. 15 Schiavinato A, Zanetto A, Pantano G, et al. Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. J Viral Hepat. 2017; 24(12): 1168–1176. DOI: 10.1111/jvh.12746
    Back to article
  16. 16 Ferri C, Antonelli A, Mascia MT, et al. HCV-related autoimmune and neoplastic disorders: The HCV syndrome. Dig Liver Dis. 2007; 39(Suppl 1): S13–S21. DOI: 10.1016/S1590-8658(07)80005-3
    Back to article
  17. 17 Spinelli JJ, Lai AS, Krajden M, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. Int J Cancer. 2008; 122(3): 630–633. DOI: 10.1002/ijc.23105
    Back to article
  18. 18 D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6): 743–753. DOI: 10.1161/CIRCULATIONAHA.107.699579
    Back to article
  19. 19 Biomy R, Abdelshafy M, Abdelmonem A, Abu-Elenin H, Ghaly G. Effect of chronic hepatitis C virus treatment by combination therapy on cardiovascular system. Clin Med Insights Cardiol. 2017; 11: 1179546817713204. Published 2017 Jun 22. DOI: 10.1177/1179546817713204
    Back to article
  20. 20 Zahno A, Brecht K, Morand R, et al. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol. 2011; 81(3): 432–441. DOI: 10.1016/j.bcp.2010.11.002
    Back to article
  21. 21 El Missiri AM, Rayan MM, Awad MM, El Desoky AI. Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring. Egypt Heart J. 2020; 72(1): 37. Published 2020 Jul 1. DOI: 10.1186/s43044-020-00070-4
    Back to article
  22. 22 Caldeira D, Rodrigues FB, Duarte MM, et al. Cardiac harms of sofosbuvir: Systematic review and meta-analysis. Drug Saf. 2018; 41(1): 77–86. DOI: 10.1007/s40264-017-0586-2
    Back to article
  23. 23 Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? J Hepatol. 2012; 56(Suppl 1): S56–S65. DOI: 10.1016/S0168-8278(12)60007-5
    Back to article
  24. 24 Gitto S, Cicero AFG, Loggi E, et al. Worsening of serum lipid profile after direct acting antiviral treatment. Ann Hepatol. 2018; 17(1): 64–75. DOI: 10.5604/01.3001.0010.7536
    Back to article
  25. 25 Mauss S, Berger F, Wehmeyer MH, et al. Effect of antiviral therapy for HCV on lipid levels. Antivir Ther. 2017; 21(1): 81–88. DOI: 10.3851/IMP3094
    Back to article
  26. 26 Meissner EG, Lee YJ, Osinusi A, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015; 61(3): 790–801. DOI: 10.1002/hep.27424
    Back to article
  27. 27 Hashimoto S, Yatsuhashi H, Abiru S, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment. PLoS One. 2016; 11(9): e0163644. Published 2016 Sep 28. DOI: 10.1371/journal.pone.0163644
    Back to article
  28. 28 Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther. 2010; 32(13): 2117–2138. DOI: 10.1016/S0149-2918(11)00022-1
    Back to article
  29. 29 Badawi A, Di Giuseppe G, Arora P. Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007–2017). PLoS One. 2018; 13(12): e0208839. Published 2018 Dec 12. DOI: 10.1371/journal.pone.0208839
    Back to article
  30. 30 Batsaikhan B, Huang CI, Yeh ML, et al. The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. Oncotarget. 2018; 9(30): 21313–21321. Published 2018 Apr 20. DOI: 10.18632/oncotarget.25092
    Back to article
  31. 31 Tran TT, Mehta D, Mensa F, Park C, Bao Y, Sanchez Gonzalez Y. Pan-genotypic hepatitis C treatment with glecaprevir and pibrentasvir for 8 weeks resulted in improved cardiovascular and metabolic outcomes and stable renal function: A post-hoc analysis of phase 3 clinical trials. Infect Dis Ther. 2018; 7(4): 473–484. DOI: 10.1007/s40121-018-0218-x
    Back to article
  32. 32 Khattab MA, Eslam M, Aly MM, et al. Serum lipids and chronic hepatitis C genotype 4: interaction and significance. Ann Hepatol. 2012; 11(1): 37–46. DOI: 10.1016/S1665-2681(19)31484-X
    Back to article
  33. 33 Cheng FK, Torres DM, Harrison SA. Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: Still important in the era of direct acting antiviral therapy? J Viral Hepat. 2014; 21(1): 1–8. DOI: 10.1111/jvh.12172
    Back to article
  34. 34 Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013; 19(7): 837–849. DOI: 10.1038/nm.3248
    Back to article
  35. 35 Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses. 2013; 5(5): 1292–1324. Published 2013 May 23. DOI: 10.3390/v5051292
    Back to article
  36. 36 Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: A systematic review. JAMA. 2014; 312(6): 631–640. DOI: 10.1001/jama.2014.7085
    Back to article
  37. 37 Meissner EG, Lee YJ, Osinusi A, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015; 61(3): 790–801. DOI: 10.1002/hep.27424
    Back to article
  38. 38 Lim TR, Hazlehurst JM, Oprescu AI, et al. Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. Clin Endocrinol (Oxf). 2019; 90(3): 440–448. DOI: 10.1111/cen.13924
    Back to article
  39. 39 El Sagheer G, Soliman E, Ahmad A, Hamdy L. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs. Libyan J Med. 2018; 13(1): 1435124. DOI: 10.1080/19932820.2018.1435124
    Back to article
  40. 40 Gualerzi A, Bellan M, Smirne C, et al. Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents. PLoS One. 2018; 13(12): e0209216. Published 2018 Dec 20. DOI: 10.1371/journal.pone.0209216
    Back to article
  41. 41 Negro F. HCV infection and metabolic syndrome: Which is the chicken and which is the egg? Gastroenterology. 2012; 142(6): 1288–1292. DOI: 10.1053/j.gastro.2011.12.063
    Back to article
  42. 42 Knobler H, Malnick S. Hepatitis C and insulin action: An intimate relationship. World J Hepatol. 2016; 8(2): 131–138. DOI: 10.4254/wjh.v8.i2.131
    Back to article
  43. 43 Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004; 165(5): 1499–1508. DOI: 10.1016/S0002-9440(10)63408-6
    Back to article
  44. 44 Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol. 2003; 98(12): 2751–2756. DOI: 10.1111/j.1572-0241.2003.08728.x
    Back to article
  45. 45 Calzadilla-Bertot L, Vilar-Gomez E, Torres-Gonzalez A, et al. Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. Dig Liver Dis. 2016; 48(3): 283–290. DOI: 10.1016/j.dld.2015.12.002
    Back to article
  46. 46 White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. J Hepatol. 2008; 49(5): 831–844. DOI: 10.1016/j.jhep.2008.08.006
    Back to article
DOI: https://doi.org/10.5334/gh.906 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Aug 21, 2020
Accepted on: Nov 23, 2020
Published on: Jan 4, 2021
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Hepatitis C Virus,
Directly Acting Antiviral Agents,
Midrange Left Ventricular Ejection Fraction

© 2021 Ahmed Farouk Alaarag, Ahmed Mohamed Hamam, Osama Ahmed Amin, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 16 (2021): Issue 1Next article